As of September 30, 2026, Braveheart Bio, Inc. carries a market capitalization of 1.82B, placing it among publicly traded companies globally. Its enterprise value stands at 1.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.82B |
| Enterprise Value | 1.47B |
Braveheart Bio, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of September 30, 2026, Braveheart Bio, Inc. has 90.04M shares outstanding.
| Shares Outstanding | 90.04M |
These figures are as of September 30, 2026.
| PB Ratio | 3.66 |
| P/TBV Ratio | 3.66 |
| P/FCF Ratio | -22.22 |
| P/OCF Ratio | -24.02 |
As of September 30, 2026, Braveheart Bio, Inc. maintains a current ratio of 21.57, meaning it holds 21.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 21.57 |
| Quick Ratio | 20.95 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | -0.01 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 21.93 |
Over the twelve months ended September 30, 2026, Braveheart Bio, Inc. generated - - in revenue and converted that into -62.22M in net income, yielding earnings per share of -1.10. EBITDA reached -68.05M, while operating income came in at -68.06M.
| Operating Income | -68.06M |
| Pretax Income | -62.22M |
| Net Income | -62.22M |
| EBITDA | -68.05M |
| EBIT | -68.06M |
| Earnings Per Share (EPS) | -1.10 |
As of September 30, 2026, Braveheart Bio, Inc. holds 349.27M in cash and equivalents against 515,000.00 in total debt, resulting in a net debt position of -121.29M. Total book value stands at 497.60M, with working capital of 342.90M providing operational flexibility.
| Cash & Cash Equivalents | 349.27M |
| Total Debt | 515,000.00 |
| Net Debt | -121.29M |
| Equity (Book Value) | 497.60M |
| Book Value Per Share | 5.53 |
| Working Capital | 342.90M |
Braveheart Bio, Inc. produced -47.78M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -3.86M in capital expenditures, free cash flow totaled -51.65M - equivalent to -0.91 per share.
| Operating Cash Flow | -47.78M |
| Capital Expenditures | -3.86M |
| Free Cash Flow | -51.65M |
| FCF Per Share | -0.91 |
These figures cover the twelve months ended September 30, 2026. The dividend payout ratio of 5.49 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -4.50: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -26.82, meaning Braveheart Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Payout Ratio | 5.49 |
| Shareholder Yield | -26.82 |
| FCF Yield | -4.50 |
As of September 30, 2026, Braveheart Bio, Inc. has an Altman Z-Score of 64.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 64.80 |